Top

Published in:

Open Access 01-11-2018 | Epidemiology

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen

Authors: M. van Nuland, R. A. Vreman, R. M. T. ten Ham, A. H. M. de Vries Schultink, H. Rosing, J. H. M. Schellens, J. H. Beijnen, A. M. Hövels

Published in: Breast Cancer Research and Treatment | Issue 1/2018

Abstract

Purpose

Breast cancer is the most common malignancy in women worldwide. Recurrence rates in breast cancer are considered to be dependent on the serum concentration of endoxifen, the active metabolite of tamoxifen. The goal of this study is to investigate the cost-effectiveness of periodically monitoring serum concentrations of endoxifen in adjuvant estrogen receptor alfa (ERα) positive breast cancer patients treated with tamoxifen in the Netherlands.

Methods

A Markov model with disease-free survival (DFS), recurrent disease (RD), and death states was constructed. The benefit of drug monitoring was modeled via a difference in the fraction of patients achieving adequate serum concentrations. Robustness of results to changes in model assumptions were tested through deterministic and probabilistic sensitivity analyses.

Results

Monitoring of endoxifen added 0.0115 quality-adjusted life-years (QALYs) and saved € 1564 per patient in the base case scenario. Deterministic sensitivity analysis demonstrated a large effect on the incremental cost-effectiveness ratio (ICER) of the differences in costs and utilities between the DFS and RD states. Probabilistic sensitivity analysis showed that the probability of cost-effectiveness at a willingness to pay of € 0 per quality-adjusted life-year (QALY) was 89.8%.

Conclusions

Based on this model, monitoring of endoxifen in adjuvant ERα + breast cancer patients treated with tamoxifen is likely to add QALYs and save costs from a healthcare payer perspective. We advise clinicians to consider integrating serum endoxifen concentration monitoring into standard adjuvant tamoxifen treatment of ERα + breast cancer patients.

Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108. https://doi.org/10.3322/caac.21262 CrossRefPubMed

Tang Y, Wang Y, Kiani MF, Wang B (2016) Classification, treatment strategy, and associated drug resistance in breast cancer. Clin Breast Cancer 16:335–343. https://doi.org/10.1016/j.clbc.2016.05.012 CrossRefPubMed

European Medicines Agency (2017) Tamoxifen summary of product characteristics. June 24, 2016 update. https://www.medicines.org.uk/emc/medicine/30769. Accessed: Oct 31 2017

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717. https://doi.org/10.1016/S0140-6736(05)66544-0 CrossRef

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) EBCTCG, Davies C, Godwin J et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784. https://doi.org/10.1016/S0140-6736(11)60993-8 CrossRef

Gray RG, Rea D, Handley K et al (2013) ATTom: LOng-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31CrossRef

Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816. https://doi.org/10.1016/S0140-6736(12)61963-1 CrossRefPubMedPubMedCentral

Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12:1101–1108. https://doi.org/10.1016/S1470-2045(11)70270-4 CrossRefPubMedPubMedCentral

Francis PA, Regan MM, Fleming GF et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436–446. https://doi.org/10.1056/NEJMoa1412379 CrossRefPubMed

10.

Madlensky L, Natarajan L, Tchu S et al (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89:718–725. https://doi.org/10.1038/clpt.2011.32 CrossRefPubMedPubMedCentral

11.

de Vries Schultink AHM, Alexi X, van Werkhoven E et al (2017) An antiestrogenic activity score for tamoxifen and its metabolites is associated with breast cancer outcome. Breast Cancer Res Treat 161:567–574. https://doi.org/10.1007/s10549-016-4083-6 CrossRefPubMed

12.

Jager NGL, Rosing H, Schellens JHM et al (2014) Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen. Breast Cancer Res Treat 146:137–144. https://doi.org/10.1007/s10549-014-2999-2 CrossRefPubMed

13.

US Food and Drug Administration (FDA) (2004) Prescribing information: nolvadex. Silver Spring, Maryl US Food Drug Adm

14.

Teunissen SF, Jager NGL, Rosing H et al (2011) Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B 879:1677–1685. https://doi.org/10.1016/j.jchromb.2011.04.011 CrossRef

15.

Khoshnoud MR, Fornander T, Johansson H, Rutqvist L-E (2008) Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen. Breast Cancer Res Treat 107:71–78. https://doi.org/10.1007/s10549-007-9520-0 CrossRefPubMed

16.

Goldhirsch A, Gelber RD, Price KN et al (1994) Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 343:377–381. https://doi.org/10.1016/S0140-6736(94)91221-1 CrossRefPubMed

17.

Borner M, Bacchi M, Goldhirsch A et al (1994) First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol 12:2071–2077. https://doi.org/10.1200/JCO.1994.12.10.2071 CrossRefPubMed

18.

Husereau D, Drummond M, Petrou S et al (2013) Consolidated health economic evaluation reporting standards (CHEERS)-explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health 16:231–250. https://doi.org/10.1016/j.jval.2013.02.002 CrossRefPubMed

19.

Pierce JP, Faerber S, Wright FA et al (2002) A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women’s Healthy Eating and Living (WHEL) Study. Control Clin Trials 23:728–756CrossRef

20.

Fox P, Balleine RL, Lee C et al (2016) Dose escalation of tamoxifen in patients with low endoxifen level: evidence for therapeutic drug monitoring-The TADE Study. Clin Cancer Res 22:3164–3171. https://doi.org/10.1158/1078-0432.CCR-15-1470 CrossRefPubMed

21.

Jager NGL, Koornstra RHT, Vincent AD et al (2013) Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. BMC Cancer 13:612. https://doi.org/10.1186/1471-2407-13-612 CrossRefPubMedPubMedCentral

22.

Dezentjé VO, Opdam FL, Gelderblom H et al (2015) CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects. Breast Cancer Res Treat 153:583–590. https://doi.org/10.1007/s10549-015-3562-5 CrossRefPubMedPubMedCentral

23.

Hoyle MW, Henley W (2011) Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol 11:139. https://doi.org/10.1186/1471-2288-11-139 CrossRefPubMedPubMedCentral

24.

Statistics Netherlands (CBS) (2015) Sterfte; geslacht, leeftijd (op 31 december) en burgerlijke staat 1950–2014 [mortality by age and sex 1950–2014]

25.

Institute for Medical Technology Assessment Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg [methodology of cost research and reference prices for economic evaluation in health care]. https://www.zorginstituutnederland.nl/binaries/zinl/documenten/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg/Richtlijn+voor+het+uitvoeren+van+economische+evaluaties+in+de+gezondheidszorg+(verdiepingsmo

26.

Dutch National Health Institute (Zorginstituut Nederland) (2016) Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg [guideline for economic evaluation in health care]

27.

Essers BAB, Seferina SC, Tjan-Heijnen VCG et al (2010) Transferability of model-based economic evaluations: the case of trastuzumab for the adjuvant treatment of her2-positive early breast cancer in the netherlands. Value Health 13:375–380. https://doi.org/10.1111/j.1524-4733.2009.00683.x CrossRefPubMed

28.

Miquel-Cases A, Retèl VP, Lederer B et al (2016) Exploratory cost-effectiveness analysis of response-guided neoadjuvant chemotherapy for hormone positive breast cancer patients. PLoS ONE 11:e0154386. https://doi.org/10.1371/journal.pone.0154386 CrossRefPubMedPubMedCentral

29.

Dutch Healthcare Authority (NZa) (2017) DBC product-finder for tariffs 2017. http://www.nza.nl/organisatie/. Accessed 30 May 2018

30.

Dutch National Health Institute (Zorginstituut Nederland) (2016) Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg [guideline for economic evaluation in health care]. https://www.zorginstituutnederland.nl/binaries/zinl/documenten/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg.pdf

31.

Briggs AH, Weinstein MC, Fenwick EAL et al (2012) Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making 32:722–732. https://doi.org/10.1177/0272989X12458348 CrossRefPubMed

32.

Jager NGL, Rosing H, Schellens JHM et al (2014) Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. Breast Cancer Res Treat 143:477–483. https://doi.org/10.1007/s10549-013-2826-1 CrossRefPubMed

33.

Neven P, Jongen L, Lintermans A et al (2018) Tamoxifen metabolism and efficacy in breast cancer: a prospective multicenter trial. Clin Cancer Res 24:2312–2318. https://doi.org/10.1158/1078-0432.CCR-17-3028 CrossRefPubMed

34.

Lintermans A, Van Asten K, Jongen L et al (2016) Prospective study evaluating the effect of impaired tamoxifen metabolisation on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting. J Clin Oncol 34:523. https://doi.org/10.1200/JCO.2016.34.15_suppl.523 CrossRef

Title: Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen
Authors: M. van Nuland
R. A. Vreman
R. M. T. ten Ham
A. H. M. de Vries Schultink
H. Rosing
J. H. M. Schellens
J. H. Beijnen
A. M. Hövels
Publication date: 01-11-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4886-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors

Perometry versus simulated circumferential tape measurement for the detection of breast cancer-related lymphedema

Screening status, tumour subtype, and breast cancer survival: a national population-based analysis

The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations

Clinical subtypes and prognosis of pregnancy-associated breast cancer: results from the Korean Breast Cancer Society Registry database

Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer